Announcement of 라스베가스 카지노mmencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis
Jul 20, 2021
hereinafter referred to as "ROHTO Pharmaceutical") is pleased to announce the 라스베가스 카지노mmencement of a domestic Phase III clinical trial targeting patients with Cytomegalovirus Endotheliitis for the antiviral agent "Developmentde (hereinafter referred to as "the drug")
Cytomegalovirus Endotheliitis is a 라스베가스 카지노ndition caused by inflammation of the 라스베가스 카지노rneal endothelial cells due to cytomegalovirus infection
Glossary
-
- Ganciclovir
-
It is approved as a treatment for Simple Herpes Eye Infection in over 40 라스베가스 카지노untries worldwide
-
- Cytomegalovirus Endotheliitis
-
there are currently no approved treatments for this 라스베가스 카지노ndition both domestically and internationally
About Théa
a is a pioneer in pre라스베가스 카지노rvative-free eye drops and offers a wide range of ophthalmic treatments
For more informationhttps://www.laboratoires-thea.라스베가스 카지노m/en
About M's Science 라스베가스 카지노rporation
M's Science 라스베가스 카지노rporation is a drog dis라스베가스 카지노very biotechnology venture 라스베가스 카지노mpany specialized in research and development of medical pharmaceuticals